Candesartan Solid Composition Plasticizer Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Candesartan, a key antihypertensive drug, faces stability issues when incorporated into solid pharmaceutical compositions, leading to decomposition and loss of its stable polymorphic form I, which existing solutions fail to adequately address, particularly in terms of maintaining chemical and physical stability during processing and storage.
Innovation Solution
Incorporating specific plasticizers such as phthalate esters, sebacates, polyacrylate polymers, and citrate esters into the composition to reduce friction between particles and stabilize candesartan cilexetil, thereby maintaining its polymorphic form I and minimizing impurities, with triethyl citrate being a preferred plasticizer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If candesartan is incorporated into a pharmaceutical composition, then it can be formulated for oral administration, but decomposition of the active ingredient is observed
Solution Approach 1:
The patent introduces an intermediary substance (plasticizer) that mediates between the candesartan crystals and the formulation matrix. This plasticizer forms a protective interface that prevents direct contact between candesartan and potentially decomposing factors in the formulation, thereby maintaining chemical stability while enabling successful formulation for oral administration
2Stability of the object's composition
If candesartan is stored individually in the solid state, then it maintains stability against temperature, moisture and light, but when incorporated into a pharmaceutical composition decomposition is observed
Solution Approach 1:
The patent applies local quality by creating a specific microenvironment around the candesartan crystals through the plasticizer. This local modification provides protective properties only where needed (at the crystal interface) while leaving the bulk formulation properties unchanged, thus preserving intrinsic stability while improving stability in formulation
3Reliability
If plasticizers are added to stabilize candesartan, then chemical and physical stability is improved, but the formulation complexity increases
Solution Approach 1:
The patent applies parameter changes by optimizing the plasticizer concentration within a specific range (0.1-10% w/w). This parameter optimization ensures sufficient stability protection while minimizing the impact on formulation complexity. The plasticizer concentration is tuned to achieve the minimum effective amount for stability without excessive addition that would complicate the formulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of these plasticizers results in a stable solid pharmaceutical composition with reduced impurities and retained polymorphic form I of candesartan cilexetil, enhancing the drug's stability and bioavailability, even under conditions like storage at 60 °C for 7 days, and facilitates effective treatment of hypertension and related diseases.
Implementation Method 1
Incorporating specific plasticizers such as phthalate esters, sebacates, polyacrylate polymers, and citrate esters into the composition to reduce friction between particles and stabilize candesartan cilexetil
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to a stable solid pharmaceutical composition comprising candesartan or its pharmaceutically acceptable forms and at least one plasticizer selected from the group consisting of phthalate esters, sebacates, alginates, citrate esters, polyacrylate and polymethacrylate polymers, polymers and copolymers of ethylene, vinyl and/or acetate, various sugar alcohols, triacetin, menthol and any mixture thereof.